Jacob Johnson
Stock Analyst at Stephens & Co.
(2.84)
# 1,620
Out of 5,147 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $252.35 | -4.89% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.90 | -13.04% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.20 | -16.67% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $26.98 | +122.39% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $210.64 | +49.54% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $521.11 | +30.49% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $128.73 | +32.06% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $2.58 | +93.80% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.81 | +1,255.85% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $15.52 | +144.85% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $8.42 | +101.90% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.56 | -2.34% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $59.00 | +47.46% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $254.34 | +53.34% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $9.83 | +83.11% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.01 | +494.06% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $24.20 | +19.83% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $198.31 | -34.45% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $178.49 | +111.22% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $252.35
Upside: -4.89%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.90
Upside: -13.04%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.20
Upside: -16.67%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $26.98
Upside: +122.39%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $210.64
Upside: +49.54%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $521.11
Upside: +30.49%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $128.73
Upside: +32.06%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $2.58
Upside: +93.80%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.81
Upside: +1,255.85%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $15.52
Upside: +144.85%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $8.42
Upside: +101.90%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.56
Upside: -2.34%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $59.00
Upside: +47.46%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $254.34
Upside: +53.34%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $9.83
Upside: +83.11%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.01
Upside: +494.06%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $24.20
Upside: +19.83%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $198.31
Upside: -34.45%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $178.49
Upside: +111.22%